- In April 2020, Polaryx Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial investigating PLX-200 as a potential treatment for juvenile Batten disease. Originally developed as a cholesterol-lowering drug, PLX-200 works by binding to its receptor, retinoid X receptor-alpha (RXRa), which triggers a series of molecular processes believed to enhance lysosome formation and function
Frequently Asked Questions
The market is segmented based on Global Neuronal Ceroid-Lipofuscinoses Market Segmentation, By Symptoms (Dementia, Vision Loss, Cerebral Atrophy, and Epilepsy), Type (Juvenile NCL, Infantile NCL (INCL), Late Infantile NCL, and Adult NCL), Treatment (Occupational Therapy and Physical Therapy), End Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031
.
The Global Neuronal Ceroid Lipofuscinoses Market size was valued at USD 39.60 USD Million in 2023.
The Global Neuronal Ceroid Lipofuscinoses Market is projected to grow at a CAGR of 6.3% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
